Navigation Links
Myriad Genetics Presents Tumor Origin Technology at AACR

Determining Tumor Origin May Be Useful in Cancer Treatment Decisions

SALT LAKE CITY, UT, April 18, 2007--Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced today that it presented studies for a new technology that might be used to determine the original location of a metastatic tumor, on Monday, April 16, 2007 at the annual meeting of the American Association for Cancer Research (AACR) in Los Angeles, California. This work could also prove helpful in determining whether any two tumors are related, and was carried out in collaboration with researchers from Magee-Womens Hospital and the University of Pittsburgh Medical Center.

Tumor origin can play an important role in choosing among treatment options for cancer patients. A difficult problem in treating some gynecological malignancies is determining the primary site of tumor origin. This is particularly apparent when cancer simultaneously involves both the ovary and endometrium. Myriad has developed a technology based on DNA copy number analysis, which may be used to accurately distinguish between the different possible originating or primary tumors.

The preliminary data from Myriad's study came from patient specimens with diagnoses of simultaneous ovarian and endometrial cancers. Three separate specimens were collected and analyzed for DNA copy number from each patient, one from the ovarian tumor, one from the endometrial tumor and one from normal unaffected tissue.

In many cases, pathologists may be unable to distinguish between related tumors and separate primary tumors due to the uncertain nature of the pathology results. The copy number analysis either confirmed conclusions from pathological examination, or provided new information that could be used to give a more positive determination of tumor source. Copy number analysis can show that both tumors share a change
'"/>




Page: 1 2 3

Related medicine technology :

1. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
2. Myriad Genetics Presents Azixas Mode of Action at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Myriad Genetics Presents Tumor Origin Technology AACR
(Date:10/22/2014)... -- Antigen Discovery Inc. (ADi), a privately held company ... receipt of a National Institutes of Health (NIH) Phase ... of Dental and Craniofacial Research (NIDCR). The one-year $225,000 ... Microarray Chip, which will contain every protein in all ... the development of safe and effective vaccines and therapies ...
(Date:10/22/2014)... 22, 2014  Paper Pak Industries, a manufacturer ... ® Body Guard Bio, a disposable, highly ... bacteria and virus while protecting service providers and ... features a rugged, external nylon shell, watertight zipper, ... leak-proof inner chamber that contains contaminated and potentially ...
(Date:10/22/2014)... , Oct. 22, 2014  With a vision ... health medications, a Global Pharmaceutical and Biotech manufacturer ... technology and turnkey solution to protect their animal ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... was serialized and aggregated by the Xyntek and ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... Ventus Medical, Inc. a privately-held medical device company ... breathing, today announced that it has received CE ... (Photo:   http://photos.prnewswire.com/prnh/20110209/SF45785-b ) ... pleased to accomplish this important regulatory milestone. Receiving ...
... Cempra Pharmaceuticals today announced the appointment of David ... well as announcing an expansion of its clinical ... programs, solithromycin and TAKSTA ... significant anti-infective clinical development experience. Solithromycin ...
Cached Medicine Technology:Ventus Medical Receives CE Mark for Provent® Sleep Apnea Therapy 2Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™ 2Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™ 3
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- Not getting the right ... colitis, a new study suggests. Those who sleep ... hours per night may be more prone to developing ... researchers report. The study authors concluded that duration and ... among patients with inflammatory bowel diseases. "Both short ...
(Date:10/25/2014)... Randy Dotinga HealthDay Reporter ... more genetic tests are developed that spot increased risks for ... more proactive about getting screened. But a new study ... change behavior: People who found out their genes doubled their ... with average risk to get screened. "It didn,t make ...
(Date:10/22/2014)... On October 22, CBS will air ... diseases both fictional and real. The Charles E ... committed to advocacy and philanthropy in the battle against ... opportunity to impart truth and clarity about this misunderstood ... many misconceptions about Morgellons Disease (MD) and ...
(Date:10/22/2014)... Amy Norton HealthDay ... Headlines remain riveted on the three Ebola cases in Dallas. ... bigger health threat to Americans. President Barack Obama on ... to the virus, which has infected two Dallas nurses who ... month at Texas Health Presbyterian Hospital. But the U.S. ...
(Date:10/22/2014)... 2014 Hay House is pleased to announce ... Upgrade Your Life (Paperback; $10.82) written by the highly esteemed ... This book is meant to help readers of all ... recovery. , Recovery 2.0 is not the average self-help ... is a guide for what comes next. For ...
Breaking Medicine News(10 mins):Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3
... from the Howard Florey Institute in Melbourne have identified ... heroin addiction by manipulating the adenosine A2A receptor, which ... , Using mice specifically bred without the adenosine A2A ... these mice had a reduced desire to self-administer morphine; ...
... translational research grant program will fund STOP Diabetes, a ... STOP project is designed to reduce the risk for ... , The STOP Diabetes project was created by investigators ... address the alarming increase in lifestyle related metabolic diseases ...
... Nepstar,Chain Drugstore Ltd. (NYSE: NPD ) (,China ... China based on the number of directly,operated stores, ... Charity,Federation to organize a program to provide relief ... province, China. Specifically, the program is,designed to encourage ...
... WASHINGTON, May 14 Tonight, the American Red,Cross ... and,corporations whose outstanding dedication and commitment enables the,organization ... This national,recognition event, held at the historic American ... Service, will bring together members of,Congress, military leaders, ...
... part in an eight-month workplace initiative reported that headaches and ... cent and their use of painkillers halved, according to research ... also reported that pain levels were less severe at the ... researchers compared 169 staff in Turins registry and tax offices ...
... at 11:00 AM ET, LIVINGSTON, N.J., May 14 ... leader in advanced,injection technologies, today announced that the Company ... March 31, 2008 on Thursday,May 15, 2008., Milestone ... beginning,at 11:00 AM Eastern time, and invites all interested ...
Cached Medicine News:Health News:Research sheds new light on heroin addiction 2Health News:International Diabetes Federation gives grant to metabolic syndrome research project in Australia 2Health News:China Nepstar Chain Drugstore Organizing An Earthquake Relief Program 2Health News:China Nepstar Chain Drugstore Organizing An Earthquake Relief Program 3Health News:American Red Cross Hosts Heritage of Service Dinner 2Health News:Office initiative reduces headaches and neck and shoulder pain by more than 40 percent 2Health News:Office initiative reduces headaches and neck and shoulder pain by more than 40 percent 3Health News:Milestone Scientific to Announce First Quarter 2008 Results on Thursday, May 15, 2008 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: